AbbVie Inc (ABBV)vsNovocure Ltd (NVCR)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
NVCR
Novocure Ltd
$15.21
+27.49%
HEALTHCARE · Cap: $1.38B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 9232% more annual revenue ($61.16B vs $655.35M). ABBV leads profitability with a 6.9% profit margin vs -20.8%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
NVCR
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+83.6%
Fair Value
$64.09
Current Price
$15.21
$48.88 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
No standout strengths identified
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -38.9% — below average capital efficiency
Earnings declined 6.0%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : NVCR
NVCR has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : NVCR
The primary concerns for NVCR are Market Cap, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while NVCR is a turnaround play — different risk/reward profiles.
NVCR carries more volatility with a beta of 0.82 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 28/100). NVCR offers better value entry with a 83.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Novocure Ltd
HEALTHCARE · MEDICAL DEVICES · USA
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?